Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT04378569) tested a cream called ARQ-252 on people with hand eczema. A total of 230 participants were enrolled across two groups, called Cohort 1 and Cohort 2. Cohort 1 was a smaller, earlier group of 7 people who received ARQ-252 cream at a 0.3% strength once daily. Cohort 2 was larger, with the remaining participants split across different versions of the cream — different strengths and how often it was applied (once or twice daily) — as well as a "vehicle cream," which is a plain cream containing no active ingredient, used for comparison purposes. The trial was measuring both how participants responded to the cream and any medical events that occurred during the study. The reported data shows that in Cohort 1, out of 7 participants, 1 person experienced at least one adverse event (an unexpected medical occurrence during the study), and no participants experienced a reaction at the application site, a serious adverse event, or notable changes in blood test results. For Cohort 2, the main thing being measured was how many participants reached a score of "clear" or "almost clear" on a 5-point scale that doctors used to rate the severity of hand eczema (where 0 means completely clear and 4 means severe). The reported data shows that at 12 weeks, 23 out of 65 participants receiving the 0.3% cream once daily, 15 out of 61 receiving the 0.3% cream twice daily, and 10 out of 32 receiving the 0.1% cream once daily reached that "clear" or "almost clear" rating. In the combined vehicle cream (plain cream, no active ingredient) group, 16 out of 65 participants reached that same rating. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Eczema Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are legally able to make your own decisions and sign a consent form
- You are 18 years old or older
- You have been diagnosed with chronic hand eczema that has either lasted more than 3 months, or has come back at least twice in the past 12 months, and has been generally stable for the last 6 weeks
- Your hand eczema covers at least roughly one-third of a handprint in total across both hands
- If you are a woman who could become pregnant, you must have negative pregnancy tests at the start of the study, and agree to use highly effective birth control plus a barrier method (such as a condom) during the study and for at least 4 weeks after the last dose
- If you are a woman who cannot become pregnant, you must either have gone through menopause (no periods for at least 12 months) or have had a surgical procedure to prevent pregnancy
- If you are a man who has sexual intercourse with a woman who is pregnant or could become pregnant, you must agree to use a condom every time during the study and for 4 weeks after the last dose
- You are considered to be in good general health, based on a doctor's review of your medical history, physical exam, heart trace (ECG), and blood and urine tests
Who may not be able to join:
- You have another skin condition on your hands that could interfere with the study results (confirm with trial site)
- You have ever had or currently have psoriasis
- You have previously had a positive patch test (allergy skin test) and are still being exposed to that allergen — you must also have had patch testing done within the last 3 years
- You are unable to stop using current treatments for your hand eczema before and during the study
- You have had a problem with alcohol or drug misuse in the past 6 months
- You are pregnant, breastfeeding, or planning to become pregnant during the study or within 28 days of the last dose
- You have a serious medical condition or significant abnormal test results that a doctor believes would make it unsafe for you to take part
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: David Berk, MD, Arcutis Biotherapeutics, Inc.
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Cohort 1: Number of Participants With ≥1 Adverse Event (AE); Cohort 1: Number of Participants With an Application Site Reaction; Cohort 1: Number of Participants With ≥1 Serious Adverse Event (SAE); Cohort 1: Number of Participants With Significant Changes in Hematology Laboratory Parameters; Cohort 1: Number of Participants With Significant Changes in Chemistry Laboratory Parameters; Cohort 2: Investigator's Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' at Week 12
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.